PhnyX Lab is a technology company.
PhnyX Lab is redefining biopharma workflows with Cheiron, an AI solution designed to eliminate wasted hours on repetitive documentation and fragmented data searches.
PhnyX Lab has raised $4.0M across 1 funding round.
PhnyX Lab has raised $4.0M in total across 1 funding round.
PhnyX Lab has raised $4.0M in total across 1 funding round.
PhnyX Lab's investors include Bonfire Ventures, SID Venture Partners.
PhnyX Lab is a Palo Alto-based AI startup developing the Cheiron platform, a biopharma AI tool that unifies internal and external data to automate pharmaceutical workflows, including intelligent document processing, AI-powered literature reviews, and regulatory compliance.[1][2][3] It targets life science companies, addressing inefficiencies in pharmaceutical research and healthcare by transforming chaotic data into actionable insights via generative AI.[1][2][3] The company recently closed a $4M SAFE seed round in August 2025, led by SK Networks with participation from AI pioneers Aidan Gomez (Cohere CEO) and Illia Polosukhin (NEAR Protocol co-founder), signaling strong early momentum in the GenAI-for-biopharma space.[3]
PhnyX Lab emerged as a pioneering GenAI startup focused on life sciences, with CEO Min-seok Bae at the helm and Sung-hwan Choi serving as Executive Advisor (also COO of SK Networks).[3] The idea crystallized around redefining biopharma workflows through AI, leading to the creation of Cheiron—a discovery platform that integrates disparate data sources.[2][3] Key traction came via the $4M SAFE round closed on August 4, 2025, backed by SK Networks and notable angels like Gomez and Polosukhin, co-authors of the seminal "Attention Is All You Need" paper that birthed transformers and modern GenAI.[3] This funding followed deep engagements with leadership, underscoring conviction in AI's pharma potential.[3]
(Note: Search results provide limited founder backstory beyond CEO and advisor; no explicit founding year is stated, though the 2025 funding marks a pivotal early milestone.[3])
PhnyX Lab stands out in AI-driven biopharma through:
PhnyX Lab rides the GenAI-in-biopharma wave, where LLMs are increasingly augmented for drug discovery, regulatory filings, and R&D acceleration amid rising data volumes.[1][2][3] Timing aligns with 2025's maturing transformer tech—directly validated by its investors' foundational work—coinciding with pharma's push for AI to cut costs and timelines in a market projected to exceed $100B by 2030 (inferred from sector trends).[3] Favorable forces include regulatory tailwinds (e.g., FDA AI pilots) and data explosion from omics/electronic health records, positioning PhnyX to streamline workflows others overlook.[1][2] It influences the ecosystem by pioneering modular AI (e.g., RAG variants), potentially setting standards for scalable pharma AI platforms.[4]
PhnyX Lab's $4M raise positions it for rapid Cheiron scaling, likely targeting enterprise pilots with biopharma giants in 2026 amid exploding AI-pharma demand.[3] Trends like agentic AI and multimodal RAG will shape its path, enhancing Cheiron for end-to-end discovery; influence may grow via SK Networks' Asia ties and angel expertise, evolving from workflow tool to ecosystem leader.[2][3][4] Watch for Series A as proof-of-value metrics emerge—PhnyX exemplifies how transformer legacies fuel the next AI frontier in life sciences.[3]
PhnyX Lab has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $4.0M Seed | Bonfire Ventures, SID Venture Partners |